Two widely disseminated strains of Enterococcus faecalis highly resistant to gentamicin and ciprofloxacin from bacteraemias in the UK and Ireland

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 4, 2003, Pages 711-714

  Woodford, Neil ^a   Reynolds, Rosy ^b   Turton, Jane ^a   Scott, Fiona ^a   Sinclair, Alistair ^a   Williams, Andrea ^a   Livermore, David ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b British Soc Antimicrob Chemother   (United Kingdom)

Author keywords

E. Faecalis; Epidemic strains; Resistance

Indexed keywords

CIPROFLOXACIN; GENOMIC DNA; GENTAMICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; GEOGRAPHIC DISTRIBUTION; IN VITRO STUDY; IRELAND; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PULSED FIELD GEL ELECTROPHORESIS; STATISTICAL ANALYSIS; UNITED KINGDOM;

BACTEREMIA; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; GENTAMICINS; GREAT BRITAIN; HUMANS; IRELAND;

EID: 0141963039     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg408     Document Type: Article

References (12)

1. Andrews, J. M. for the BSAC Working Party On Susceptibility Testing. (2001). BSAC standardized disc susceptibility testing method. Journal of Antimicrobial Chemotherapy 48, Suppl. S1, 43-57.
2. Chow, J. W. (2000). Aminoglycoside resistance in enterococci. Clinical Infectious Diseases 31, 586-9.
3. Onodera, Y., Okuda, J., Tanaka, M. et al. (2002). Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV of Enterococcus faecalis. Antimicrobial Agents and Chemotherapy 46, 1800-4.
4. Ruiz, J. (2003). Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. Journal of Antimicrobial Chemotherapy 51, 1109-17.
5. Carias, L. L., Rudin, S. D., Donskey, C. J. et al. (1998). Genetic linkage and cotransfer of a novel, vanB-containing transposon (Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin-resistant Enterococcus faecium isolate. Journal of Bacteriology 180, 4426-34.
6. Andrews, J. M. (2001). Determination of minimum inhibitory concentrations. Journal of Antimicrobial Chemotherapy 48, Suppl. S1, 5-16.
7. Dutka-Malen, S., Evers, S. & Courvalin, P. (1995). Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. Journal of Clinical Microbiology 33, 24-7.
8. Woodford, N., Morrison, D., Johnson, A. P. et al. (1995). Plasmid-mediated vanB glycopeptide resistance in enterococci. Microbial Drug Resistance 1, 235-40.
9. Woodford, N., Morrison, D., Cookson, B. et al. (1993). Comparison of high-level gentamicin-resistant Enterococcus faecium isolates from different continents. Antimicrobial Agents and Chemotherapy 37, 681-4.
10. Weinbren, M. J., Johnson, A. P. & Woodford, N. (2000). Defining high-level gentamicin resistance in enterococci. Journal of Antimicrobial Chemotherapy 45, 404-5.
11. Eaton, T. J. & Gasson, M. J. (2001). Molecular screening of Enterococcus virulence determinants and potential for genetic exchange between food and medical isolates. Applied and Environmental Microbiology 67, 1628-35.
12. Hällgren, A., Saeedi, B., Nilsson, M. et al. (2003). Genetic relatedness among Enterococcus faecalis with transposon-mediated high-level gentamicin resistance in Swedish intensive care units. Journal of Antimicrobial Chemotherapy 52, 162-7.